- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06336837
False Positive Peripheral Blood Culture in Children With Leukaemia: A Prevalence Study
Chemotherapy, the main treatment for childhood leukemia, has side effects on healthy cells. One of the most important of these side effects is the risk of infection due to neutropenia. In clinics, blood culture is the gold standard for the detection of possible infection risk (bacteremia, fungemia, etc.). During the diagnosis and treatment process in children with leukemia, a large number of peripheral or catheter blood cultures are performed. When the culture results are positive, it is accepted that the infection has grown. In some cases, a positive peripheral blood culture result may not be clinically significant. An agent belonging to the skin flora of the patient or the healthcare professional taking the field culture may also cause the blood culture result to be positive. This is called contamination or false positive blood culture. Contaminated cultures may cause prolonged hospitalization, additional medical interventions, unnecessary initiation of antibiotic treatment and related antibiotic resistance, toxicity due to additional drugs and an increase in hospital costs. The peripheral blood culture contamination rate, which is accepted as a quality indicator in some countries, should be below 3%.
In this context, this study aimed to determine the prevalence of false positive peripheral blood cultures by examining the peripheral blood culture results obtained during routine follow-ups from children hospitalized with leukemia in the pediatric hematology clinic. The data will be collected retrospectively covering three years before March 2024 when the ethics committee approval was obtained. Since the relevant clinic cares for approximately 25 new children diagnosed with leukemia annually, the study sample is planned as 75 cases.
Study Overview
Status
Conditions
Detailed Description
A positive peripheral blood culture does not always mean that the individual has a systemic infection. In some cases, a positive blood culture result may also be seen in the event of contamination with the skin flora of the person receiving/receiving the culture. This is called a false positive blood culture. This situation is characterised as a situation that reduces the reliability of the test. Contaminated false positive blood culture is a single culture bottle containing microorganisms belonging to the skin flora (Coagulase Negative Staphylococcus [Staphylococcus epidermidis, Staphylococcus hominis, Staphylococcus capitis, Staphylococcus haemolyticus], Viridans streptococci, Aerococcus, Micrococcus, Propionibacterium spp, Bacillus spp., [except B. Anthracis], Corynebacterium spp. and alpha-gamma haemolytic streptococci, Dermabacter spp., Rothia spp. and Kocuria spp.)
In cases where bacteria grow in blood culture media, it is necessary to distinguish between local skin flora and true pathogenic bacteria. Contaminated culture results in prolonged hospital stay, additional tests, unnecessary exposure of the patient to antimicrobial agents and increased risk of other complications (qualitative change in microorganisms, increased colonisation rates with drug-resistant organisms such as VRE and MRSA, increased Clostridium difficile infection rates). Inappropriate antibiotherapies initiated due to contaminated blood culture results may cause toxic side effects in the patient. One of the most serious negative effects of inappropriately used antibiotics is the development of antibiotic resistance. Due to the large-scale use of inappropriate antibiotics in hospitals, nosocomial flora undergoes a change. This change leads to the disappearance of susceptible microorganisms in the flora and the increase in resistant strains.
In this context, the aim of this study was to determine the prevalence of false positive peripheral blood cultures by retrospectively examining the peripheral blood culture results obtained during routine follow-up from children hospitalised with leukaemia in the paediatric haematology clinic.
Type of Research Quantitative | Descriptive | Archive Search
Population and Sample The population of the research will consist of children who received chemotherapy due to leukemia treatment and whose peripheral blood culture was taken during routine treatment. The sample will consist of pediatric patients who were hospitalized in the Hematology Department Clinic of Ege University Faculty of Medicine Children's Hospital between March 2021 and March 2024 (after the approval of the Ethics Committee, retrospectively from the month of approval (3 years)). Since the number of inpatient cases diagnosed with leukemia in the Pediatric Hematology Clinic is approximately 25 cases per year, it is planned to examine the peripheral blood culture results of 75 different cases in three years.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
İzmir, Turkey, 35100
- Ege University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- within the time interval of the study being a patient between the ages of 0-18,
- not having any other disease other than leukaemia,
- having received inpatient chemotherapy treatment in PHO
- having a peripheral blood culture test taken from the patient,
- the patient's culture results being accessible through the hospital information system.
Exclusion Criteria:
- the patient was hospitalised in the clinic outside the time frame of the study,
- a diagnosis other than leukaemia
- peripheral blood culture was not taken from the patient or the results could not be accessed through the hospital information system
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
No arm used.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
blood culture contamination rate
Time Frame: three year period
|
false positive peripheral blood culture
|
three year period
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 24-3T/48
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia
-
Stanford UniversityTerminatedLeukemia | Leukemia, Lymphocytic, Acute | Leukemia Acute Promyelocytic Leukemia (APL) | Leukemia Acute Lymphoid Leukemia (ALL) | Leukemia Chronic Myelogenous Leukemia (CML) | Leukemia Acute Myeloid Leukemia (AML) | Leukemia Chronic Lymphocytic Leukemia (CLL)United States
-
Massachusetts General HospitalCelgene CorporationTerminatedAcute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States
-
Institute of Hematology & Blood Diseases HospitalBejing Institute for Stem Cell and Regenerative Medicine; Institute for Stem...RecruitingRefractory Leukemia | Relapsed Leukemia | Acute Myeloid Leukemia, ChildhoodChina
-
Hybrigenics CorporationUnknownAcute Myelogenous LeukemiaUnited States, France
-
Betta Pharmaceuticals Co., Ltd.Not yet recruitingAcute Myeloid Leukemia LeukemiaChina
-
Massachusetts General HospitalCompleted
-
Kinex Pharmaceuticals Inc.CompletedAcute Myelogenous LeukemiaUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...CompletedAcute Lymphoblastic Leukemia | Acute Myelogenous Leukemia (AML) | Acute Lymphocytic Leukemia (ALL) | Acute Promyelocytic Leukemia (APL)United States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Megakaryocytic Leukemia (M7) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States